Immunosuppression of rat myasthenia gravis by oral administration of a syngeneic acetylcholine receptor fragment

Journal of Neuroimmunology

Volumn 152, Issue 1-2, 2004, Pages 112-120

  Maiti, Prasanta K ^a   Feferman, Tali ^a   Im, Sin Hyeog ^a,c   Souroujon, Miriam C ^a,b   Fuchs, Sara ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b OPEN UNIVERSITY OF ISRAEL   (Israel)

^c Gwangju Institute of Science and Technology (GIST)   (South Korea)

Author keywords

Autoimmunity; Mucosal tolerance; Myasthenia gravis; Th1 Th2 cells

Indexed keywords

ACETYLCHOLINE RECEPTOR ALPHA; CANCER GROWTH FACTOR; CD28 ANTIGEN; CHOLINERGIC RECEPTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 10; MESSENGER RNA; PROTEIN SUBUNIT; RECOMBINANT PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNITY; AUTOREGULATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; IMMUNOSUPPRESSIVE TREATMENT; MYASTHENIA GRAVIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; TH1 CELL; TH2 CELL; UPREGULATION;

ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSION; INTERFERON TYPE II; INTERLEUKIN-10; MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL; PEPTIDES; RATS; RATS, INBRED LEW; RECEPTORS, NICOTINIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TH1 CELLS; TH2 CELLS; TRANSPLANTATION, HETEROLOGOUS; TRANSPLANTATION, ISOGENEIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 3042656879     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2004.04.010     Document Type: Article

References (49)

1. Aharonov A., Tarrab-Hazdai R., Silman I., Fuchs S. Immunochemical studies on acetylcholine receptor fraction from Torpedo californica. Immunochemistry. 14:1977;129-137
2. Baggi F.A.F., Caspani E., Milani M., Longhi R., Mantegazza R., Cornelio F., Antozzi C. Oral administration of an immunodominant T-cell epitope downregulates Th1/Th2 cytokines and prevents experimental myasthenia gravis. J. Clin. Invest. 104:1999;1287-1295
3. Balasa B., Deng C., Lee J., Bradley L.M., Dalton D.K., Christadoss P., Sarvetnick N. Interferon gamma (IFN-gamma) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice. J. Exp. Med. 186:1997;385-391
4. Balasa B., Krahl T., Patstone G., Lee J., Tisch R., McDevitt H.O., Sarvetnick N. CD40 ligand-CD40 interactions are necessary for the initiation of insulitis and diabetes in nonobese diabetic mice. J. Immunol. 159:1997;4620-4627
5. Bartfeld D., Fuchs S. Specific immunosupression of experimental autoimmune myasthenia gravis by denatured acetylcholine receptor. Proc. Natl. Acad. Sci. U. S. A. 75:1978;4006-4010
6. Beeson D., Morris A., Vincent A., Newson-Davis J. The human muscle nicotinic acetylcholine receptor a-subunit exists as two isoforms: a novel exon. EMBO J. 9:1990;2101-2106
7. Carayanniotis G., Masters S.R., Noelle R.J. Suppression of murine thyroiditis via blockade of the CD40-CD40L interaction. Immunology. 90:1997;421-426
8. Drachman D.B. Immunotherapy in neuromuscular disorders: current and future strategies. Muscle Nerve. 19:1996;1239-1251
9. Durie F.H., Fava R.A., Foy T.M., Aruffo A., Ledbetter J.A., Noelle R.J. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science. 261:1993;1328-1330
10. Faria A.M., Maron R., Ficker S.M., Slavin A.J., Spahn T., Weiner H.L. Oral tolerance induced by continuous feeding: enhanced up-regulation of transforming growth factor-beta/interleukin-10 and suppression of experimental autoimmune encephalomyelitis. J. Autoimmun. 20:2003;135-145
11. Finck B., Linsley P.S., Wofsy D. Treatment of murine lupus with CTLA4Ig. Science. 265:1994;1225-1227
12. Gerritse K., Laman J.D., Noelle R.J., Aruffo A., Ledbetter J.A., Boersma W.J., Claassen E. CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 93:1996;2499-2504
13. Girvin A.M., DalCanto M.C., Rhee L., Salomon B., Sharpe A., Bluestone J.A., Miller S.D. A critical role for B7/CD28 costimulation in experimental autoimmune encephalomyelitis: a comparative study using costimulatory molecule-deficient mice and monoclonal antibody blockade. J. Immunol. 164:2000;136-143
14. Grewal I.S., Xu J., Flavell R.A. Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand. Nature. 378:1995;617-620
15. Grewal I.S., Foellmer H.G., Grewal K.D., Xu J., Hardardottir F., Baron J.L., Janeway C.A. Jr., Flavell R.A. Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis. Science. 273:1996;1864-1867
16. Griggs N.D., Agersborg S.S., Noelle R.J., Ledbetter J.A., Linsley P.S., Tung K.S. The relative contribution of the CD28 and gp39 costimulatory pathways in the clonal expansion and pathogenic acquisition of self-reactive T cells. J. Exp. Med. 183:1996;801-810
17. Howard M., O'Garra A. Biological properties of IL-10. Immunol. Today. 13:1992;198-200
18. Im S.H., Barchan D., Fuchs S., Souroujon M.C. Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment. J. Clin. Invest. 104:1999;1723-1730
19. Im S.H., Barchan D., Fuchs S., Souroujon M.C. Mechanism of nasal tolerance induced by a recombinant fragment of acetylcholine receptor for treatment of experimental myasthenia gravis. J. Neuroimmunol. 111:2000;161-168
20. Im S.H., Barchan D., Souroujon M.C., Fuchs S. Role of tolerogen conformation in induction of oral tolerance in experimental autoimmune myasthenia gravis. J. Immunol. 165:2000;3599-3605
21. Im S.H., Barchan D., Maiti P., Raveh L., Souroujon M., Fuchs S. Suppression of experimental myasthenia gravis, a B cell-mediated autoimmune disease, by blockade of IL-18. FASEB J. 15:2001;2140-2148
22. Im S.H., Barchan D., Maiti P.K., Fuchs S., Souroujon M.C. Blockade of CD40L suppresses chronic experimental myasthenia gravis by down-regulation of Th1 differentiation and upregulation of CTLA-4. J. Immunol. 166:2001;6893-6898
23. Karachunski P.I., Ostlie N.S., Okita D.K., Conti-Fine B.M. Prevention of experimental myasthenia gravis by nasal administration of synthetic acetylcholine receptor T epitope sequences. J. Clin. Invest. 100:1997;3027-3035
24. Karachunski P.I., Ostlie N.S., Monfardini C., Conti-Fine B.M. Absence of IFN-gamma or IL-12 has different effects on experimental myasthenia gravis in C57BL/6 mice. J. Immunol. 164:2000;5236-5244
25. Karandikar N., Vanderlugt C.L., Walunas T.L., Miller S.D., Bluestone J.A. CTLA-4: a negative regulator of autoimmune disease. J. Exp. Med. 184:1996;783-788
26. Kennedy M.K., Mohler K.M., Shanebeck K.D., Baum P.R., Picha K.S., Otten-Evans C.A., Janeway C.A. Jr., Grabstein K.H. Induction of B cell costimulatory function by recombinant murine CD40 ligand. Eur. J. Immunol. 24:1994;116-123
27. Koshy M., Berger D., Crow M.K. Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J. Clin. Invest. 98:1996;826-837
28. Lennon V.A., Lambert E.H., Leiby K.R., Okarma T.B., Talib S. Recombinant human acetylcholine receptor alpha-subunit induces chronic experimental autoimmune myasthenia gravis. J. Immunol. 146:1991;2245-2248
29. Lenschow D.J., Walunas T.L., Bluestone J.A. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14:1996;233-258
30. Ma C.G., Zhang G.X., Xiao B.G., Link J., Olsson T., Link H. Suppression of experimental autoimmune myasthenia gravis by nasal administration of acetylcholine receptor. J. Neuroimmunol. 58:1995;51-60
31. Matusevicius D., Navikas V., Palasik W., Pirskanen R., Fredrikson S., Link H. Tumor necrosis factor-alpha, lymphotoxin, interleukin (IL)-6, IL-10, IL-12 and perforin mRNA expression in mononuclear cells in response to acetylcholine receptor is augmented in myasthenia gravis. J. Neuroimmunol. 71:1996;191-198
32. McIntosh K.R., Linsley P.S., Drachman D.B. Immunosuppression and induction of anergy by CTLA4Ig in vitro: effects on cellular and antibody responses of lymphocytes from rats with experimental autoimmune myasthenia gravis. Cell. Immunol. 1660:1995;103-112
33. Mohan C., Shi Y., Laman J.D., Datta S.K. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J. Immunol. 154:1995;1470-1480
34. Moiola L., Galbiati F., Martino G., Amadio S., Brambilla E., Comi G., Vincent A., Grimaldi L.M., Adorini L. IL-12 is involved in the induction of experimental autoimmune myasthenia gravis, an antibody-mediated disease. Eur. J. Immunol. 28:1998;2487-2497
35. Mukherjee S., Maiti P.K., Nandi D. Role of CD80, CD86, and CTLA4 on mouse CD4(+) T lymphocytes in enhancing cell-cycle progression and survival after activation with PMA and ionomycin. J. Leukoc. Biol. 72:2002;921-931
36. Okumura S., McIntosh K., Drachman D.B. Oral administration of acetylcholine receptor: effects on experimental myasthenia gravis. Ann. Neurol. 36:1994;704-713
37. Parker D.C. T cell-ependent B cell activation. Annu. Rev. Immunol. 11:1993;331-360
38. Poussin M.A., Goluszko E., Hughes T.K., Duchicella S.I., Christadoss P. Suppression of experimental autoimmune myasthenia gravis in IL-10 gene-disrupted mice is associated with reduced B cells and serum cytotoxicity on mouse cell line expressing AChR [In Process Citation]. J. Neuroimmunol. 111:2000;152-160
39. Reynolds J., Tam F.W., Chandraker A., Smith J., Karkar A.M., Cross J., Peach R., Sayegh M.H., Pusey C.D. CD28-B7 blockade prevents the development of experimental autoimmune glomerulonephritis. J. Clin. Invest. 105:2000;643-651
40. Roy M., Aruffo A., Ledbetter J., Linsley P., Kehry M., Noelle R. Studies on the interdependence of gp39 and B7 expression and function during antigen-specific immune responses. Eur. J. Immunol. 25:1995;596-603
41. Shi F.D., Bai X.F., Xiao B.G., van der Meide P.H., Link H. Nasal administration of multiple antigens suppresses experimental autoimmune myasthenia gravis, encephalomyelitis and neuritis. J. Neurol. Sci. 155:1998;1-12
42. Shi F.D., He B., Li H., Matusevicius D., Link H., Ljunggren H.G. Differential requirements for CD28 and CD40 ligand in the induction of experimental autoimmune myasthenia gravis. Eur. J. Immunol. 28:1998;3587-3593
43. Stout R.D., Suttles J., Xu J., Grewal I.S., Flavell R.A. Impaired T cell-mediated macrophage activation in CD40 ligand-deficient mice. J. Immunol. 156:1996;8-11
44. Teleshova N., Matusevicius D., Kivisakk P., Mustafa M., Pirskanen R., Link H. Altered expression of costimulatory molecules in myasthenia gravis. Muscle Nerve. 23:2000;946-953
45. Thompson C. Distinct roles for the costimulatory ligands B7-1 and B7-2 in T helper cell differentiation? Cell. 81:1995;979-982
46. Walunas T.L., Lenschow D.J., Bakker C.Y., Linsley P.S., Freemann G.J., Green J.M., Thompson C.B., Bluestone J.A. CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1:1994;405-413
47. Wang Z.Y., Qiao J., Link H. Suppression of experimental autoimmune myasthenia gravis by oral administration of acetylcholine receptor. J. Neuroimmunol. 44:1993;209-214
48. Wang H.B., Li H., Shi F.D., Chambers B.J., Link H., Ljunggren H.G. Tumor necrosis factor receptor-1 is critically involved in the development of experimental autoimmune myasthenia gravis. Int. Immunol. 12:2000;1381-1388
49. Zhang G., Xiao B., Yu L., van der Meide P.H., Link H. Interleukin 10 aggravates experimental autoimmune myasthenia gravis through inducing Th2 and B cell responses to AChR. J. Neuroimmunol. 113:2001;10-18